Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 91

Similar articles for PubMed (Select 22870440)

1.

The efficacy and safety of abatacept in rheumatoid arthritis.

Westhovens R, Verschueren P.

Ther Adv Musculoskelet Dis. 2010 Apr;2(2):89-94. doi: 10.1177/1759720X09360429.

2.
3.

Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists.

Isaacs JD.

Expert Opin Biol Ther. 2009 Dec;9(12):1463-75. doi: 10.1517/14712590903379494. Review.

PMID:
19916731
4.

Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy.

Genovese MC, Schiff M, Luggen M, Becker JC, Aranda R, Teng J, Li T, Schmidely N, Le Bars M, Dougados M.

Ann Rheum Dis. 2008 Apr;67(4):547-54. Epub 2007 Oct 5.

PMID:
17921185
5.

Description of the efficacy and safety of three new biologics in the treatment of rheumatoid arthritis.

Storage SS, Agrawal H, Furst DE.

Korean J Intern Med. 2010 Mar;25(1):1-17. doi: 10.3904/kjim.2010.25.1.1. Epub 2010 Feb 26. Review.

6.

A critical evaluation of the role of subcutaneous abatacept in the treatment of rheumatoid arthritis: patient considerations.

Wells AF, Jodat N, Schiff M.

Biologics. 2014 Feb 17;8:41-55. doi: 10.2147/BTT.S55783. eCollection 2014. Review.

7.

How do the efficacy and safety of abatacept and infliximab compare in the treatment of active RA?

Taylor PC.

Nat Clin Pract Rheumatol. 2009 Mar;5(3):126-7. doi: 10.1038/ncprheum1022.

PMID:
19252515
8.

Safety profile of abatacept in rheumatoid arthritis: a review.

Khraishi M, Russell A, Olszynski WP.

Clin Ther. 2010 Oct;32(11):1855-70. doi: 10.1016/j.clinthera.2010.10.011. Review.

PMID:
21095481
9.

Comparative clinical utility of once-weekly subcutaneous abatacept in the management of rheumatoid arthritis.

Rakieh C, Conaghan PG.

Ther Clin Risk Manag. 2014 Apr 30;10:313-20. doi: 10.2147/TCRM.S60740. eCollection 2014. Review.

10.

Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapy.

Genovese MC, Schiff M, Luggen M, Le Bars M, Aranda R, Elegbe A, Dougados M.

J Rheumatol. 2012 Aug;39(8):1546-54. doi: 10.3899/jrheum.111531. Epub 2012 Jul 15.

PMID:
22798265
11.

Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.

Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, Birbara C, Box J, Natarajan K, Nuamah I, Li T, Aranda R, Hagerty DT, Dougados M.

N Engl J Med. 2005 Sep 15;353(11):1114-23. Erratum in: N Engl J Med. 2005 Nov 24;353(21):2311.

12.

Abatacept in biologic-naïve patients and TNF inadequate responders: clinical data in focus.

Sherrer Y.

Curr Med Res Opin. 2008 Aug;24(8):2283-94. doi: 10.1185/03007990802223129. Epub 2008 Jun 27. Review.

PMID:
18590608
13.

Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial.

Westhovens R, Cole JC, Li T, Martin M, Maclean R, Lin P, Blaisdell B, Wallenstein GV, Aranda R, Sherrer Y.

Rheumatology (Oxford). 2006 Oct;45(10):1238-46. Epub 2006 Mar 27.

14.

Abatacept: a T-cell co-stimulation modulator for the treatment of rheumatoid arthritis.

Ostör AJ.

Clin Rheumatol. 2008 Nov;27(11):1343-53. doi: 10.1007/s10067-008-0964-3. Epub 2008 Aug 1. Erratum in: Clin Rheumatol. 2008 Nov;27(11):1477.

PMID:
18670735
15.

[A novel treatment option in rheumatoid arthritis: abatacept, a selective modulator of T-cell co-stimulation].

Dejaco C, Duftner C, Wipfler E, Schirmer M.

Wien Med Wochenschr. 2009;159(3-4):70-5. doi: 10.1007/s10354-008-0590-3. Review. German.

PMID:
19247593
16.

Abatacept in the long-term treatment of rheumatoid arthritis.

Jani M, Hyrich KL.

Expert Rev Clin Immunol. 2012 Mar;8(3):231-4. doi: 10.1586/eci.11.98.

PMID:
22390487
17.

Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry.

Leffers HC, Ostergaard M, Glintborg B, Krogh NS, Foged H, Tarp U, Lorenzen T, Hansen A, Hansen MS, Jacobsen MS, Dreyer L, Hetland ML; all departments of rheumatology in Denmark.

Ann Rheum Dis. 2011 Jul;70(7):1216-22. doi: 10.1136/ard.2010.140129. Epub 2011 May 8.

PMID:
21551512
18.

Treatment options for rheumatoid arthritis beyond TNF-α inhibitors.

Yazici Y, Simsek I.

Expert Rev Clin Pharmacol. 2010 Sep;3(5):663-6. doi: 10.1586/ecp.10.47.

PMID:
22111748
20.

Newer biological agents in the treatment of rheumatoid arthritis: do the benefits outweigh the risks?

Nurmohamed MT.

Drugs. 2009 Oct 22;69(15):2035-43. doi: 10.2165/11318290-000000000-00000.

PMID:
19791825
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk